Current Therapies to Target HDL – Update on Clinical Trials

1 ACPE 1 ANCC Contract Hours 1 CDR 1 AMA PRA Category 1 Credit(s)™
Launch Date:
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

No primary audience was provided.

Relevant Terms:

No primary audience was provided.

Benjamin J. Ansell, MD, FNLA*

Benjamin J. Ansell, MD, FNLA*
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, CA

Peter H. Jones, MD

Peter H. Jones, MD
Associate Professor of Medicine
Section of Atherosclerosis and Lipid Research
Methodist Debakey Heart and Vascular Center
Baylor College of Medicine
Center for Cardiovascular Disease Prevention
Director, Weight Management Center
The Methodist Hospital
Houston, TX

Peter H. Jones, MD, is an Associate Professor of Medicine and a Co-Director of the Lipid Metabolism and Atherosclerosis Clinic in the Section of Atherosclerosis and Vascular Medicine at Baylor College of Medicine in Houston, Texas. Dr. Jones is also a member of the Center for Cardiovascular Disease Prevention at the Methodist DeBakey Heart and Vascular Center in Houston. He is a specialist in the clinical management of lipid disorders and has participated in numerous clinical trials of various drugs and their effects on lipid metabolism, including all of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Dr. Jones served as Chair of the Morbidity/Mortality Review Committee for the Lipoprotein Coronary Atherosclerosis Study (LCAS); for this study, the angiographic evaluation of fluvastatin effectiveness was performed at Baylor College of Medicine. He also served as Director of the American Heart Association Lipid Disorders Training Program at Baylor College of Medicine, which involved lectures and workshops on the clinical management of dyslipidemias. Most recently, he participated in obesity drug studies, particularly involving leptin. Dr. Jones is the Medical Director of the Methodist Wellness Services at The Methodist Hospital. He sees private patients for treatment of lipid disorders and for general medical care and serves as an attending physician in general medicine at The Methodist Hospital, the Ben Taub General Hospital, and the Michael E. DeBakey Veterans Affairs Medical Center.

Laurence S. Sperling, MD, FACC, FAHA, FACP

Laurence S. Sperling, MD, FACC, FAHA, FACP
The Emory Clinic
Professor of Medicine
Medical Director of Preventive Cardiology Clinic
Atlanta, GA

Laurence S. Sperling, M.D., FACC, FAHA, FACP is the Founder and Director of Preventive Cardiology at the Emory Clinic and Co-Director of the Cardiovascular Disease Fellowship Program at Emory. He is currently Professor of Medicine (Cardiology) at the Emory University School of Medicine. He was awarded The American College of Cardiology Harry B. Graf Career Development Award for Heart Disease Prevention and The American Heart Association Council on Clinical Cardiology Scholarship for Physical Activity and Public Health in 2001.
Dr. Sperling is originally from New York. He received his undergraduate degree from Emory College where he was accepted into Emory University School of Medicine's Early Acceptance Program as a college sophomore. He graduated with his M.D. in 1989, and subsequently completed 8 additional years of training at Emory including a residency in internal medicine, chief resident year at Emory University Hospital, an NIH-supported research fellowship in molecular and vascular medicine, and a clinical fellowship in cardiovascular diseases.
Dr. Sperling serves or has served as medical director for a number of unique programs at Emory including The HeartWise Risk Reduction Program, InterVent Atlanta, Staying Aloft, and has served as special consultant to The Centers for Disease Control. He founded (in 2004) and directs the first and only LDL apheresis program in the state of Georgia. He has been voted one of America's and Atlanta's Top Doctors and appeared often on local and national TV, newspaper, radio, and magazines. In 2011 he was chosen as one of 22 national dietary experts by U.S. News and World Report to evaluate and rank America's popular diets. He has received awards for excellence in both teaching (including 3 Golden Apple Awards) and mentorship. He was chosen by the Dean at Emory University School of Medicine to be among the first faculty society advisors for the school's new curriculum. He had served as Associate Director of the Cardiovascular Fellowship Training program at Emory for over a decade. He has been an investigator in a number of important clinical trials including JUPITER, COURAGE, and BARI-2D and has authored over 100 manuscripts, abstracts, and book chapters. He is co-editor of the American College of Cardiology's Diabetes Self Assessment Program.
Dr. Sperling has been a marathon runner having completed the New York, Prague, and Atlanta marathons. In 2010 he ran the original course from Marathon to Athens, Greece to celebrate the 2500th anniversary of this event. He lives in the Druid Hills neighborhood of Atlanta with his wife, Sidney, and 2 sons, Mathew and Daniel.
1. Compare the relative effectiveness of existing treatments to raise HDL and reduce CVD risk
2. For Registered Nurses and Nurse Practitioners Only: Provide appropriate care and counsel for patients and their families